Proactiveinvestors USA & Canada BioPorto https://ca.proactiveinvestors.com Proactiveinvestors USA & Canada BioPorto RSS feed en Thu, 12 Dec 2019 19:20:09 -0500 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) BioPorto places focus on flagship NGAL kidney-injury test https://ca.proactiveinvestors.com/companies/news/219607/bioporto-places-focus-on-flagship-ngal-kidney-injury-test-219607.html Tue, 26 Nov 2019 12:00:00 -0500 https://ca.proactiveinvestors.com/companies/news/219607/bioporto-places-focus-on-flagship-ngal-kidney-injury-test-219607.html BioPorto's 3Q revenue increases 24% year-over-year https://ca.proactiveinvestors.com/companies/news/907576/bioporto-s-3q-revenue-increases-24-year-over-year-907576.html Thu, 21 Nov 2019 15:18:00 -0500 https://ca.proactiveinvestors.com/companies/news/907576/bioporto-s-3q-revenue-increases-24-year-over-year-907576.html BioPorto to provide additional patient data to back FDA application for NGAL test https://ca.proactiveinvestors.com/companies/news/907305/bioporto-to-provide-additional-patient-data-to-back-fda-application-for-ngal-test-907305.html Mon, 18 Nov 2019 20:07:00 -0500 https://ca.proactiveinvestors.com/companies/news/907305/bioporto-to-provide-additional-patient-data-to-back-fda-application-for-ngal-test-907305.html BioPorto sees boost in revenue in second quarter https://ca.proactiveinvestors.com/companies/news/900896/bioporto-sees-boost-in-revenue-in-second-quarter-900896.html Thu, 15 Aug 2019 21:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/900896/bioporto-sees-boost-in-revenue-in-second-quarter-900896.html BioPorto reveals 'healthy growth' in second quarter revenue https://ca.proactiveinvestors.com/companies/news/900875/bioporto-reveals--healthy-growth--in-second-quarter-revenue-900875.html Thu, 15 Aug 2019 14:33:00 -0400 https://ca.proactiveinvestors.com/companies/news/900875/bioporto-reveals--healthy-growth--in-second-quarter-revenue-900875.html BioPorto optimistic over FDA clearance for its NGAL kidney diagnostic test for use on children https://ca.proactiveinvestors.com/companies/news/314284/bioporto-optimistic-over-fda-clearance-for-its-ngal-kidney-diagnostic-test-for-use-on-children-14284.html Wed, 31 Jul 2019 17:09:00 -0400 https://ca.proactiveinvestors.com/companies/news/314284/bioporto-optimistic-over-fda-clearance-for-its-ngal-kidney-diagnostic-test-for-use-on-children-14284.html BioPorto completes private placing, raising around US$5.5M net https://ca.proactiveinvestors.com/companies/news/223074/bioporto-completes-private-placing-raising-around-us55m-net-223074.html Fri, 28 Jun 2019 15:30:00 -0400 https://ca.proactiveinvestors.com/companies/news/223074/bioporto-completes-private-placing-raising-around-us55m-net-223074.html Diagnostic company BioPorto taps Christopher Bird as chief medical officer https://ca.proactiveinvestors.com/companies/news/222871/diagnostic-company-bioporto-taps-christopher-bird-as-chief-medical-officer-222871.html Wed, 26 Jun 2019 14:45:00 -0400 https://ca.proactiveinvestors.com/companies/news/222871/diagnostic-company-bioporto-taps-christopher-bird-as-chief-medical-officer-222871.html BioPorto private placement of more than 9.2 million shares fully subscribed https://ca.proactiveinvestors.com/companies/news/222269/bioporto-private-placement-of-more-than-92-million-shares-fully-subscribed-222269.html Mon, 17 Jun 2019 19:54:00 -0400 https://ca.proactiveinvestors.com/companies/news/222269/bioporto-private-placement-of-more-than-92-million-shares-fully-subscribed-222269.html BioPorto submits kidney-injury test in children to FDA https://ca.proactiveinvestors.com/companies/news/313560/bioporto-submits-kidney-injury-test-in-children-to-fda-13560.html Mon, 03 Jun 2019 12:56:00 -0400 https://ca.proactiveinvestors.com/companies/news/313560/bioporto-submits-kidney-injury-test-in-children-to-fda-13560.html BioPorto submits FDA application for approval of its proprietary kidney-injury test for use in children https://ca.proactiveinvestors.com/companies/news/220338/bioporto-submits-fda-application-for-approval-of-its-proprietary-kidney-injury-test-for-use-in-children-220338.html Wed, 15 May 2019 14:16:00 -0400 https://ca.proactiveinvestors.com/companies/news/220338/bioporto-submits-fda-application-for-approval-of-its-proprietary-kidney-injury-test-for-use-in-children-220338.html BioPorto's 1Q revenue increases 20% partly on sales of its flagship NGAL Test https://ca.proactiveinvestors.com/companies/news/219991/bioporto-s-1q-revenue-increases-20-partly-on-sales-of-its-flagship-ngal-test-219991.html Thu, 09 May 2019 14:30:00 -0400 https://ca.proactiveinvestors.com/companies/news/219991/bioporto-s-1q-revenue-increases-20-partly-on-sales-of-its-flagship-ngal-test-219991.html BioPorto reports 20% increase in revenue growth for 1Q https://ca.proactiveinvestors.com/companies/news/313281/bioporto-reports-20-increase-in-revenue-growth-for-1q-13281.html Thu, 09 May 2019 14:15:00 -0400 https://ca.proactiveinvestors.com/companies/news/313281/bioporto-reports-20-increase-in-revenue-growth-for-1q-13281.html BioPorto names Amy Winslow president of US subsidiary as it prepares FDA applications https://ca.proactiveinvestors.com/companies/news/218619/bioporto-names-amy-winslow-president-of-us-subsidiary-as-it-prepares-fda-applications-218619.html Mon, 15 Apr 2019 20:00:00 -0400 https://ca.proactiveinvestors.com/companies/news/218619/bioporto-names-amy-winslow-president-of-us-subsidiary-as-it-prepares-fda-applications-218619.html BioPorto Diagnostics A/S looks for FDA approval for its kidney diagnostic test https://ca.proactiveinvestors.com/companies/news/311832/bioporto-diagnostics-as-looks-for-fda-approval-for-its-kidney-diagnostic-test-11832.html Mon, 14 Jan 2019 14:06:00 -0500 https://ca.proactiveinvestors.com/companies/news/311832/bioporto-diagnostics-as-looks-for-fda-approval-for-its-kidney-diagnostic-test-11832.html